Bitte achten Sie darauf, dass die Produkte auerhalb der Reichweite von Kindern aufbewahrt werden
limit consumption if sensitive to berries
Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management, administered as a once-weekly injection
When considering these medications, patients should note: Wegovy demonstrates up to 20% reduction in cardiovascular events Qsymia may lower blood pressure but lacks specific cardiovascular benefit data Both medications are contraindicated during pregnancy and breastfeeding Individual medical histories must guide selection, with special consideration for thyroid conditions with Wegovy Neither medication replaces the foundation of reduced caloric intake and increased physical activity for sustainable weight management
Studies have not been done in humans to see if semaglutide increases the chance of miscarriage, though animal studies have reported a higher chance for miscarriage
This precision-medicine approach increases the likelihood of meaningful, sustained weight loss
